Inicio>>NH2-PEG9-acid

NH2-PEG9-acid

Catalog No.GC61969

NH2-PEG9-Ácido es un enlazador ADC de PEG de 9 unidades no escindible que se utiliza en la sÍntesis de conjugados de anticuerpo-fÁrmaco (ADC). El Ácido NH2-PEG9 también es un conector PROTAC basado en PEG que se puede utilizar en la sÍntesis de PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

NH2-PEG9-acid Chemical Structure

Cas No.: 756526-04-2

Tamaño Precio Disponibilidad Cantidad
100 mg
20,00 $
Disponible
500 mg
239,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NH2-PEG9-acid is a non-cleavable 9 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs)[1]. NH2-PEG9-acid also is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[2].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1]. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. Michael Nathaniel ALONSO, et al. Antibody adjuvant conjugates. WO2018009916A1.
[2]. "An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562."

Reseñas

Review for NH2-PEG9-acid

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NH2-PEG9-acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.